Last reviewed · How we verify
adjuvant therapy
Adjuvant therapy enhances the body's immune response to cancer.
Adjuvant therapy enhances the body's immune response to cancer. Used for Breast cancer, Colorectal cancer, Lung cancer.
At a glance
| Generic name | adjuvant therapy |
|---|---|
| Also known as | Standard of Care |
| Sponsor | Far Eastern Memorial Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Adjuvant therapy works by stimulating the immune system to recognize and attack cancer cells more effectively. This can be achieved through various methods, such as increasing the production of immune cells or activating immune cells to target cancer cells more efficiently.
Approved indications
- Breast cancer
- Colorectal cancer
- Lung cancer
- Melanoma
- Pancreatic cancer
Common side effects
- Fatigue
- Pain
- Infection
- Nausea
- Diarrhea
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares (NA)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (PHASE2)
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma (PHASE2)
- Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- adjuvant therapy CI brief — competitive landscape report
- adjuvant therapy updates RSS · CI watch RSS
- Far Eastern Memorial Hospital portfolio CI